₹1,950.1
▼ -1.37 -0.07%
16 Jul 2026
NSE Listed
Sun Pharmaceutical Ind Limited (SUNPHARMA)
Volume: 22,83,494Avg Vol 1W: 19,27,027.6Avg Vol 1M: 20,31,851.8552W Range:₹1,548₹1,962.7
Key Ratios
Checked 15h agoMarket Cap₹4,68,230 Cr
Current Price₹1,950.1
Previous Close₹1,951.47
High / Low (52w)₹1,962.7 / ₹1,548
Volume22,83,494
Avg Vol (1W)19,27,027.6
Avg Vol (1M)20,31,851.85
Stock P/E172.7
Book Value₹348.31
Dividend Yield82%
ROE13.74%
ROA10.63%
Revenue (TTM)₹61,674 Cr
Revenue Growth8.4%
Profit Margin19.72%
Total Debt₹3 Cr
Shares Outstanding240 Cr
Face Value₹1
EPS (TTM)₹51.8
P/B5.61
Debt / Equity0.04
50 DMA₹1,857.08
200 DMA₹1,760.99
Day change-0.07%
Price Chart
₹1,950.1▲ 14.64% · 1Y
2025-07-162026-07-15
20-day avg volume: 20.3L shares
Pros
- Pays a dividend yield of 82.0%.
- Company is almost debt-free.
Cons
- Revenue fell 10% YoY.
- Stock trades at a high P/E of 173.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹12,653 Cr | ₹13,291 Cr | ₹13,675 Cr | ₹12,959 Cr | ₹13,851 Cr | ₹14,478 Cr | ₹15,521 Cr | ₹14,612 Cr |
| EBITDA | ₹3,485 Cr | ₹3,667 Cr | ₹3,844 Cr | ₹3,665 Cr | ₹4,066 Cr | ₹4,267 Cr | ₹4,795 Cr | ₹3,637 Cr |
| Net Profit | ₹2,836 Cr | ₹3,040 Cr | ₹2,903 Cr | ₹2,150 Cr | ₹2,279 Cr | ₹3,118 Cr | ₹3,369 Cr | ₹2,714 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹30,091 Cr | ₹33,489 Cr | ₹34,357 Cr | ₹39,730 Cr | ₹44,520 Cr | ₹49,887 Cr | ₹54,729 Cr | ₹61,674 Cr |
| EBITDA | ₹5,580 Cr | ₹5,573 Cr | ₹7,247 Cr | ₹9,175 Cr | ₹9,752 Cr | ₹11,821 Cr | ₹14,661 Cr | ₹16,765 Cr |
| Net Profit | ₹2,665 Cr | ₹3,765 Cr | ₹2,904 Cr | ₹3,273 Cr | ₹8,474 Cr | ₹9,576 Cr | ₹10,929 Cr | ₹11,479 Cr |
| EPS | 11.1 | 15.7 | 12.1 | 13.6 | 35.3 | 39.9 | 45.6 | 47.8 |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹64,694 Cr | ₹68,252 Cr | ₹67,667 Cr | ₹69,808 Cr | ₹80,744 Cr | ₹85,500 Cr | ₹92,101 Cr | ₹1,08,785 Cr |
| Total Liabilities | ₹19,971 Cr | ₹19,128 Cr | ₹18,187 Cr | ₹18,742 Cr | ₹21,428 Cr | ₹18,374 Cr | ₹19,615 Cr | ₹24,905 Cr |
| Equity | ₹44,723 Cr | ₹49,125 Cr | ₹49,480 Cr | ₹51,066 Cr | ₹59,315 Cr | ₹67,126 Cr | ₹72,486 Cr | ₹83,880 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating | ₹3,083 Cr | ₹7,901 Cr | ₹7,173 Cr | ₹8,015 Cr | ₹6,469 Cr | ₹13,704 Cr | ₹14,549 Cr | ₹14,733 Cr |
| Investing | ₹-681 Cr | ₹-2,589 Cr | ₹536 Cr | ₹-5,725 Cr | ₹-7,944 Cr | ₹-690 Cr | ₹-5,306 Cr | ₹-11,344 Cr |
| Financing | ₹-2,731 Cr | ₹-5,715 Cr | ₹-5,980 Cr | ₹-5,193 Cr | ₹2,376 Cr | ₹-6,710 Cr | ₹-7,906 Cr | ₹-2,513 Cr |
| Free Cash Flow | ₹3,083 Cr | ₹7,901 Cr | ₹7,173 Cr | ₹8,015 Cr | ₹6,469 Cr | ₹13,704 Cr | ₹14,549 Cr | ₹14,733 Cr |
Shareholding
Promoter 54.48% Institutions 37.04% Public 8.48%
Efficiency & Working Capital
ROCE17.3%
Interest Coverage45.6
Dividend Payout—
Debtor Days97 d
Inventory Days72 d
Payable Days46 d
Cash Conversion Cycle123 d
Working Capital Days169 d
Shareholding Details
As of 2026-03-31
Promoter54.5%
FII15.9%
DII21.1%
Institutions37%
Public8.5%
Promoter Pledge1.4%
No. of Shareholders6,90,957
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% | 54.5% |
| FIIs | 16.5% | 16.8% | 17.1% | 17.7% | 17.2% | 18% | 18% | 18% | 17.3% | 16.6% | 16.1% | 15.9% |
| DIIs | 19.8% | 19.7% | 18% | 18.8% | 19.3% | 18.6% | 18.5% | 18.7% | 19.5% | 20.2% | 20.8% | 21.1% |
| Public | 9.3% | 9.1% | 10.5% | 9% | 9% | 8.9% | 8.9% | 8.9% | 8.8% | 8.7% | 8.6% | 8.5% |
| Promoter Pledge | 2.3% | 2.4% | 2.4% | 2.1% | 1.1% | 0.8% | 0.7% | 0.9% | 0.9% | 1% | 1% | 1.4% |
| No. of Shareholders | 6,24,561 | 6,16,588 | 6,12,626 | 6,31,392 | 6,73,217 | 6,57,317 | 6,89,623 | 7,04,983 | 7,23,770 | 7,43,877 | 7,10,900 | 6,90,957 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Shanghvi Finance Private Limited | Shareholding of Promoter and Promoter Group | 40.3% | 96.71 Cr |
| Dilip.s.shanghvi | Shareholding of Promoter and Promoter Group | 9.6% | 23.04 Cr |
| Life Insurance Corporation Of India | Public Shareholding | 5.2% | 12.56 Cr |
| Icici Prudential Value Fund | Public Shareholding | 3.7% | 8.92 Cr |
| Sbi Nifty 50 Etf | Public Shareholding | 2.1% | 5.00 Cr |
| Nps Trust A/c Uti Pension Fund Limited-scheme State Govt | Public Shareholding | 1.8% | 4.25 Cr |
| Aditya Medisales Limited | Shareholding of Promoter and Promoter Group | 1.7% | 4.02 Cr |
| Raksha Sudhir Valia | Shareholding of Promoter and Promoter Group | 1.2% | 2.88 Cr |
| Government Pension Fund Global | Public Shareholding | 1.1% | 2.54 Cr |
| Lakshdeep Investments & Finance (p) Ltd. | Public Shareholding | 1% | 2.44 Cr |
| Sudhir Vrundavandas Valia | Shareholding of Promoter and Promoter Group | 0.6% | 1.43 Cr |
| Unimed Investments Limited | Shareholding of Promoter and Promoter Group | 0.4% | 1.04 Cr |
| Vibha Dilip Shanghvi | Shareholding of Promoter and Promoter Group | 0.4% | 88,40,280 |
| Aalok Dilip Shanghvi | Shareholding of Promoter and Promoter Group | 0.1% | 28,77,280 |
| Vidhi Dilip Shanghvi | Shareholding of Promoter and Promoter Group | 0.1% | 28,22,427 |
| Shanghvi Family & Friends Benefit Trust | Shareholding of Promoter and Promoter Group | 0.1% | 12,76,774 |
| Kumud Shantilal Shanghvi | Shareholding of Promoter and Promoter Group | 0% | 85,000 |
| Krishna Vrundavandas Valia | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Flamboyawer Finance Private Limited | Shareholding of Promoter and Promoter Group | 0% | 20,865 |
| Sanghvi Properties Private Limited | Shareholding of Promoter and Promoter Group | 0% | 15,479 |
| Gujarat Sun Pharmaceutical Industries Pvt Ltd | Shareholding of Promoter and Promoter Group | 0% | 14,362 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Dilip.s.shanghvi | 0 | 0% | 2026-03-31 |
| Sudhir Vrundavandas Valia | 0 | 0% | 2026-03-31 |
| Vibha Dilip Shanghvi | 0 | 0% | 2026-03-31 |
| Aalok Dilip Shanghvi | 0 | 0% | 2026-03-31 |
| Vidhi Dilip Shanghvi | 0 | 0% | 2026-03-31 |
| Kumud Shantilal Shanghvi | 85,000 | 100% | 2026-03-31 |
| Krishna Vrundavandas Valia | 0 | 0% | 2026-03-31 |
| Shanghvi Family & Friends Benefit Trust | 0 | 0% | 2026-03-31 |
| Raksha Sudhir Valia | 1.84 Cr | 64% | 2026-03-31 |
| Unimed Investments Limited | 0 | 0% | 2026-03-31 |
| Shanghvi Finance Private Limited | 0 | 0% | 2026-03-31 |
| Aditya Medisales Limited | 0 | 0% | 2026-03-31 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Dilip S Shanghvi | Chairman & Managing Director | 2025 |
| Gautam Doshi | Non Executive & Independent Director | 2025 |
| Pawan Goenka | Lead Independent Director | 2025 |
| Rama Bijapurkar | Independent Director | 2025 |
| Anoop Deshpande | Company Sec. & Compli. Officer | 2025 |
| Rolf Hoffmann | Independent Director | 2025 |
| Aalok Shanghvi | Whole Time Director & Chief Operating Officer | 2025 |
| Vidhi Shanghvi | Whole Time Director | 2025 |
| Kirti Wardhaman Ganorkar | Managing Director | 2025 |
| Satyavati Berera | Independent Director | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticals | ₹0 Cr | — |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹3,102 Cr | 42.7% |
| Outside India | ₹4,161 Cr | 57.3% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹1 | 617 | 240 | 240 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-07-31 | Board Meetings | — |
| forthcoming | 2026-07-07 | Dividend (5/- per share) | Final |
| dividend | 2026-07-07 | ₹5 (500%) | Final |
| dividend | 2026-02-05 | ₹11 (1100%) | Interim |
| dividend | 2025-07-07 | ₹5.5 (550%) | Final |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 47,800 | 16 | 0 | 28 | 105 | 47,949 |
| 2026 | 28,289 | 13 | 0 | 0 | 13 | 28,314 |
| 2026 | 2,960 | 3 | 0 | 28 | 87 | 3,078 |
Insider / Designated-Person Trades
30 recent disclosure(s)
Raksha Valia RevisedPledge · 10,00,000
Raksha Valia RevisedPledge · 20,20,000
Raksha Valia-Person Acting in Concert and immediate relative of Non Executive Non Independent Director Member of Promoter GroupPledge · 20,20,000
Raksha Valia-Person Acting in Concert and immediate relative of Non Executive Non Independent Director Member of Promoter Group RevisedPledge · 16,50,000
Raksha Valia-Person Acting in Concert and immediate relative of Non Executive Non Independent Director Member of Promoter Group RevisedPledge · 24,20,000
Raksha Valia-Person Acting in Concert and immediate relative of Non Executive Non Independent Director Member of Promoter Group RevisedPledge · 11,90,000
Substantial Acquisitions (SAST)
2 disclosure(s)
Market13/01/2026 · 2,02,500
Release of Shares19/09/2022 · —
Company Information
🌐 www.sunpharma.com ↗
📍 Sun Pharma Advanced Res.Centre, Tandalja, Vadodara, Gujarat, 390020
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search